TLCD3A

Across TCGA pan-cancer cohorts, TLCD3A RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TLCD3A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TLCD3A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TLCD3A is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, HNSC, and COAD are the cancer types where TLCD3A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TLCD3A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+1.944	<.001	12	view →
HNSC	Male	All	+1.260	<.001	12	view →
COAD	Female	II,III,IV	+1.779	<.001	11	view →
KIRP	All	III,IV	+1.597	<.001	10	view →
LUSC	Male	All	+1.492	<.001	9	view →
LIHC	Male	II,III,IV	+1.125	<.001	8	view →
KICH	Female	II,III,IV	−1.791	<.001	7	view →
LUAD	Male	II,III,IV	+0.849	<.001	7	view →
THCA	Female	II,III,IV	+0.641	<.001	7	view →
UCEC	All	All	+0.979	<.001	6	view →
CHOL	Male	All	+4.115	<.001	5	view →
STAD	Male	All	+0.863	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TLCD3A–KIRC

Open the KIRC breakdown →